Inflammatory bowel diseases have an impact on the prognosis of multiple sclerosis, according to a study published in PLOS One.
The US Food and Drug Administration (FDA) approved Genzyme’s application to include new information about its multiple sclerosis drug teriflunomide (Aubagio) on its label. The new labeling content is efficacy and safety data from two Phase III trials of the drug.
The body’s immune system can be “taught” not to attack its own cells, such as in the case of multiple sclerosis, according to research published in Nature Communications.
Doses of prepared human placenta culture cells are safe for multiple sclerosis patients, according to a study published in Multiple Sclerosis and Related Disorders.
Slow processing speed appears to explain executive deficits in multiple sclerosis patients, according to research published in Rehabilitation Psychology.
Patients with the relapsing-remitting form of multiple sclerosis have shown improvement with glatiramer acetate. Although it is unclear exactly how the drug works, recently published research has shed light on the ways in which glatiramer acetate affects B cells.